September 8, 2023 – A series of pre-clinical studies provide important first steps in developing techniques of robotic bladder transplantation in humans, as reported in the October issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
"Our study is the first report of bladder auto-transplantation in heart-beating, brain-dead human research donors as a necessary preparatory step toward clinical bladder transplantation in living patients," comments Inderbir S. Gill, MD, of Keck School of Medicine, University of Southern California, Los Angeles.
Preclinical studies to prepare for first clinical bladder transplant
Although transplantation is an accepted treatment for many types of organ failure, human urinary bladder transplantation has never been performed. That reflects, in part, the daunting technical challenges entailed in such a procedure, including the difficulty of obtaining surgical access to the deep pelvis and the complex anatomy of the blood vessels in that area.
Patients with terminal bladder conditions which render the bladder unusable may undergo surgery to remove the bladder (cystectomy). This is followed by some type of diversion procedure to restore urinary function, typically using a segment of the patient's own bowel tissue. Although these reconstructive procedures have a high success rate, they carry a substantial risk of short- and long-term complications.
Dr. Gill and his team, including Dr. Nima Nassiri, performed a series of fundamental pre-clinical studies to develop the technique of robotic bladder transplantation. Their experience included three models of auto-transplantation – removing the bladder and associated tissues, including arteries, veins, and ureters; preparing it as if from a human donor; and transplanting the prepared organ back into the donor.
-
Living animal model. Initial experiments were performed in pigs, due to the general similarity of the urinary tract and blood vessels to human anatomy.
-
Human cadaver model. This was followed by a pulsatile human cadaver model, designed to simulate blood flow in a living patient.
-
Beating-heart donor model. Similar techniques were then carried out in beating-heart, deceased donors who had been declared brain-dead. This phase included five subjects whose families had consented to organ donation but were ineligible due to other illnesses.
Techniques developed in the animal and cadaver models were successfully applied to the beating-heart donors. In all three models, operative times for robotic auto-transplantation decreased with experience. In the beating-heart donors, total surgical time decreased from 10.5 to 4.7 hours.
Bladder transplant could be a 'viable treatment option' for selected patients
Three out of four attempts at robotic auto-transplantation in beating-heart donors were successful, resulting in good blood flow to the transplanted bladder. In one case, the donor was maintained on life support for 12 hours to confirm the continued viability of the transplanted bladder.
Compared to open surgery, the robotic approach was felt to significantly facilitate donor cystectomy (bladder removal) surgery because of its superior technical access into the deep pelvis and blood vessel control. The online version of the article includes a link to a video where urologists can view key steps of the robotic auto-transplantation technique. Based on this rigorous pre-clinical developmental work, Dr. Gill and colleagues are preparing for the initial feasibility clinical trial of human bladder transplantation.
If the technique of bladder transplantation can be successfully developed and refined, it could become "a viable treatment option in a minority of well-selected and well-counseled patients," the researchers conclude. They emphasize the many unanswered questions that remain – including the long-term functioning of the transplanted bladder, the need for lifelong immunosuppressive therapy to prevent organ rejection, and patient acceptance of bladder transplant versus standard urinary diversion procedures.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
###
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,0900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
Journal
The Journal of Urology
Article Publication Date
8-Sep-2023